SLC2A1 and neoplasm: Envisaging novel targetable markers, recent glycoproteomics and bioinformatics data has pinpointed GLUT1 as a potential BLCA biomarker due to its increased expression in tumours compared to healthy tissues and its minimal potential for off-target effects [8].